• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by TScan Therapeutics Inc.

    3/5/25 4:28:14 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRX alert in real time by email
    S-8 1 d824752ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 5, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    TSCAN THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   82-5282075
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    830 Winter Street

    Waltham, Massachusetts

      02451
    (Address of Principal Executive Offices)   (Zip Code)

    TSCAN THERAPEUTICS, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN

    TSCAN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plan)

     

     

    Gavin MacBeath

    Chief Executive Officer

    TScan Therapeutics, Inc.

    830 Winter Street

    Waltham, Massachusetts 02451

    (Name and address of agent for service)

     

     

    (857) 399-9500

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Mitchell S. Bloom, Esq.

    William D. Collins, Esq.

    Finnbarr Murphy, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers (i) 5,187,143 additional shares of the Registrant’s common stock, $0.0001 par value per share (“Common Stock”), under the TScan Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”) and (ii) 565,906 additional shares of Common Stock under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1, beginning in 2022, by an amount equal to the lower of (i) four percent of the number of shares of our common stock outstanding (including the shares of our common stock underlying outstanding pre-funded warrants) on the immediately preceding December 31 and (ii) an amount of shares determined by our Board of Directors. Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the 2021 Plan increased by 5,187,143. The additional shares are of the same class as other securities relating to the 2021 Plan for which the Registrant’s registration statements filed on Form S-8 with the Securities and Exchange Commission on July 16, 2021 (Registration No.  333-257941), March 9, 2022 (Registration No.  333-263380), March 8, 2023 (Registration No.  333-270343) June 16, 2023 (Registration No.  333-272733), March 6, 2024 (Registration No.  333-277695) and June 14, 2024 (Registration No. 333-280212) are effective. The number of shares of Common Stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1, beginning in 2022, by an amount equal to the least of (i) one percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such number of shares of Common Stock as determined by our Board of Directors. Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the 2021 ESPP increased by 565,906. The additional shares are of the same class as other securities relating to the 2021 ESPP for which the Registrant’s registration statements filed on Form S-8 with the Securities and Exchange Commission on July 16, 2021 (Registration No. 333-257941), March 9, 2022 (Registration No.  333-263380), March 8, 2023 (Registration No.  333-270343) and March 6, 2024 (Registration No. 333-277695), are effective. The information contained in the Registrant’s registration statements on Form S-8 (Registration No. 333-257941, No. 333-263380, No. 333-270343 and No. 333-272733, Registration No. 333-277695 and Registration No. 333-280212) is hereby incorporated by reference pursuant to General Instruction E.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

     

    Exhibit
    No.
      

    Description

      4.1    Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40603) filed with the Securities and Exchange Commission on July 20, 2021).
      4.2    Amended and Restated By-laws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40603) filed with the Securities and Exchange Commission on July 20, 2021).
      5.1*    Opinion of Goodwin Procter LLP.
     23.1*    Consent of Deloitte & Touche LLP, independent registered public accounting firm.
     23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
     24.1*    Power of Attorney (included on signature page).
     99.1    TScan Therapeutics, Inc. 2021 Amended and Restated Equity Incentive Plan and form of agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 14, 2024).
     99.2    2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-255491) filed with the Securities and Exchange Commission on April 23, 2021).
    107.1*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on March 5, 2025.

     

    TScan Therapeutics, Inc.
    By:  

    /s/ Gavin MacBeath

      Gavin MacBeath, Ph.D.
     

    Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gavin MacBeath and Jason A. Amello, and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for such person in such person’s, place and stead, in any and all capacities, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 of TScan Therapeutics, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Gavin MacBeath

    Gavin MacBeath

       Chief Executive Officer and Director (Principal Executive Officer)   March 5, 2025

    /s/ Jason A. Amello

    Jason A. Amello

       Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)   March 5, 2025

    /s/ Stephen Biggar

    Stephen Biggar, M.D., Ph.D.

       Director   March 5, 2025

    /s/ Barbara Klencke, M.D.

    Barbara Klencke, M.D.

       Director   March 5, 2025

    /s/ Garry Nicholson

    Garry Nicholson

       Director   March 5, 2025

    /s/ Gabriela Gruia

    Gabriela Gruia, M.D.

       Director   March 5, 2025

    /s/ Katina Dorton

    Katina Dorton, J.D., M.B.A.

       Director   March 5, 2025

    /s/ R. Keith Woods

    R. Keith Woods

       Director   March 5, 2025
    Get the next $TCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRX

    DatePrice TargetRatingAnalyst
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    8/10/2021$21.00Buy
    Jefferies
    More analyst ratings

    $TCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vice President, Finance Dworak Leiden

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:39 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Zdraveski Zoran

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:41 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:52:57 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported fina

      5/6/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

      WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentation Details: Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell TransplantationAuthors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, R

      4/28/25 4:53:52 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Th

      3/31/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Financials

    Live finance-specific insights

    See more
    • TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

      All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

      2/26/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

      WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

      3/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

      8/12/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

      WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors

      4/8/24 8:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/16/24 4:26:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $4,114 worth of shares (947 units at $4.34) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      11/19/24 4:26:43 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $26,450 worth of Voting Common Stock (5,000 units at $5.29), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      9/24/24 5:26:24 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:40:11 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:05:31 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 3:05:59 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TScan Therapeutics Inc.

      10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:30:20 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:15:10 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TScan Therapeutics Inc.

      EFFECT - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/17/25 12:15:08 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on TScan Therapeutics with a new price target

      BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00

      5/16/24 7:35:53 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on TScan Therapeutics with a new price target

      Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00

      5/13/24 8:33:06 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on TScan Therapeutics with a new price target

      Wedbush initiated coverage of TScan Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/22/23 7:30:31 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care